vs

Side-by-side financial comparison of Sprout Social, Inc. (SPT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $120.9M, roughly 1.3× Sprout Social, Inc.). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 12.9%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $9.9M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 11.8%).

Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

SPT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.3× larger
TARS
$151.7M
$120.9M
SPT
Growing faster (revenue YoY)
TARS
TARS
+115.5% gap
TARS
128.4%
12.9%
SPT
More free cash flow
TARS
TARS
$3.1M more FCF
TARS
$13.0M
$9.9M
SPT
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
11.8%
SPT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SPT
SPT
TARS
TARS
Revenue
$120.9M
$151.7M
Net Profit
$-8.4M
Gross Margin
77.6%
Operating Margin
-9.0%
-5.3%
Net Margin
-5.5%
Revenue YoY
12.9%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$-0.18
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SPT
SPT
TARS
TARS
Q4 25
$120.9M
$151.7M
Q3 25
$115.6M
$118.7M
Q2 25
$111.8M
$102.7M
Q1 25
$109.3M
$78.3M
Q4 24
$107.1M
$66.4M
Q3 24
$102.6M
$48.1M
Q2 24
$99.4M
$40.8M
Q1 24
$96.8M
$27.6M
Net Profit
SPT
SPT
TARS
TARS
Q4 25
$-8.4M
Q3 25
$-9.4M
$-12.6M
Q2 25
$-12.0M
$-20.3M
Q1 25
$-11.2M
$-25.1M
Q4 24
$-23.1M
Q3 24
$-17.1M
$-23.4M
Q2 24
$-16.9M
$-33.3M
Q1 24
$-13.6M
$-35.7M
Gross Margin
SPT
SPT
TARS
TARS
Q4 25
77.6%
Q3 25
77.7%
Q2 25
77.7%
Q1 25
77.3%
Q4 24
78.1%
Q3 24
77.4%
Q2 24
77.5%
Q1 24
76.8%
Operating Margin
SPT
SPT
TARS
TARS
Q4 25
-9.0%
-5.3%
Q3 25
-7.9%
-12.2%
Q2 25
-11.0%
-21.6%
Q1 25
-10.2%
-33.5%
Q4 24
-12.8%
-36.8%
Q3 24
-16.4%
-52.3%
Q2 24
-16.6%
-81.6%
Q1 24
-13.7%
-136.5%
Net Margin
SPT
SPT
TARS
TARS
Q4 25
-5.5%
Q3 25
-8.1%
-10.6%
Q2 25
-10.7%
-19.8%
Q1 25
-10.3%
-32.1%
Q4 24
-34.8%
Q3 24
-16.6%
-48.7%
Q2 24
-17.0%
-81.6%
Q1 24
-14.0%
-129.4%
EPS (diluted)
SPT
SPT
TARS
TARS
Q4 25
$-0.18
$-0.17
Q3 25
$-0.16
$-0.30
Q2 25
$-0.21
$-0.48
Q1 25
$-0.19
$-0.64
Q4 24
$-0.25
$-0.57
Q3 24
$-0.30
$-0.61
Q2 24
$-0.30
$-0.88
Q1 24
$-0.24
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SPT
SPT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$95.3M
$417.3M
Total DebtLower is stronger
$40.0M
$72.4M
Stockholders' EquityBook value
$203.4M
$343.4M
Total Assets
$523.1M
$562.2M
Debt / EquityLower = less leverage
0.20×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SPT
SPT
TARS
TARS
Q4 25
$95.3M
$417.3M
Q3 25
$90.6M
$401.8M
Q2 25
$101.5M
$381.1M
Q1 25
$100.9M
$407.9M
Q4 24
$86.4M
$291.4M
Q3 24
$82.9M
$317.0M
Q2 24
$80.9M
$323.6M
Q1 24
$69.2M
$298.5M
Total Debt
SPT
SPT
TARS
TARS
Q4 25
$40.0M
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$25.0M
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
SPT
SPT
TARS
TARS
Q4 25
$203.4M
$343.4M
Q3 25
$194.1M
$335.1M
Q2 25
$184.6M
$332.6M
Q1 25
$175.3M
$342.5M
Q4 24
$166.6M
$224.5M
Q3 24
$158.1M
$237.5M
Q2 24
$152.1M
$252.2M
Q1 24
$147.3M
$275.2M
Total Assets
SPT
SPT
TARS
TARS
Q4 25
$523.1M
$562.2M
Q3 25
$481.4M
$534.6M
Q2 25
$422.9M
$495.0M
Q1 25
$424.7M
$500.8M
Q4 24
$428.3M
$377.0M
Q3 24
$388.8M
$376.3M
Q2 24
$393.6M
$376.8M
Q1 24
$389.9M
$349.3M
Debt / Equity
SPT
SPT
TARS
TARS
Q4 25
0.20×
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.15×
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SPT
SPT
TARS
TARS
Operating Cash FlowLast quarter
$10.9M
$19.3M
Free Cash FlowOCF − Capex
$9.9M
$13.0M
FCF MarginFCF / Revenue
8.2%
8.6%
Capex IntensityCapex / Revenue
0.9%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$39.3M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SPT
SPT
TARS
TARS
Q4 25
$10.9M
$19.3M
Q3 25
$9.3M
$18.3M
Q2 25
$5.1M
$-29.4M
Q1 25
$18.1M
$-20.7M
Q4 24
$4.1M
$-22.2M
Q3 24
$9.0M
$-8.7M
Q2 24
$2.1M
$-14.4M
Q1 24
$11.2M
$-37.8M
Free Cash Flow
SPT
SPT
TARS
TARS
Q4 25
$9.9M
$13.0M
Q3 25
$8.5M
$16.3M
Q2 25
$4.2M
$-30.4M
Q1 25
$16.7M
$-21.2M
Q4 24
$3.3M
$-22.3M
Q3 24
$8.5M
$-8.9M
Q2 24
$1.6M
$-15.4M
Q1 24
$10.1M
$-38.0M
FCF Margin
SPT
SPT
TARS
TARS
Q4 25
8.2%
8.6%
Q3 25
7.4%
13.8%
Q2 25
3.7%
-29.6%
Q1 25
15.3%
-27.1%
Q4 24
3.0%
-33.5%
Q3 24
8.3%
-18.6%
Q2 24
1.6%
-37.8%
Q1 24
10.4%
-137.5%
Capex Intensity
SPT
SPT
TARS
TARS
Q4 25
0.9%
4.2%
Q3 25
0.7%
1.6%
Q2 25
0.8%
1.0%
Q1 25
1.2%
0.8%
Q4 24
0.8%
0.1%
Q3 24
0.5%
0.6%
Q2 24
0.5%
2.5%
Q1 24
1.1%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons